Viral Oncogenesis: How Infections Drive Cancer Development

Viruses cause ~15–20% of human cancers worldwide. Oncogenic viruses share molecular strategies that subvert cellular controls.

Major Oncogenic Viruses and Associated Cancers

Common Oncogenic Strategies

  1. Oncogene expression / tumor suppressor inactivation: Viral proteins directly target p53, pRb, and pathways (PI3K/Akt, MAPK, Wnt, NF-κB).
  2. Genomic instability: Integration (HBV, HPV, MCPyV), ROS, replication stress, impaired DNA repair.
  3. Chronic inflammation: Persistent infection → cytokine milieu (TNF-α, IL-6, ROS) → mutagenesis, promotion.
  4. Immune evasion: MHC downregulation, checkpoint upregulation, immunosubversion → escape surveillance.
  5. Epigenetic reprogramming: Viral proteins recruit DNMTs, HDACs → silence tumor suppressors.
  6. Cellular immortalization: Telomerase activation (hTERT), bypass senescence.

Prevention and Control

  • Vaccination: HPV (9-valent), HBV — highly effective primary prevention.
  • Antivirals: HBV/HCV treatment reduces HCC risk.
  • Screening: Cervical (HPV test/Pap), HCC (US + AFP q6mo in cirrhosis).
  • Blood safety: HCV/HBV screening.

Understanding viral oncogenesis enables targeted prevention, early detection, and mechanism-based therapies.

Viral Infections - Related Articles

Health Sciences © https://www.222health.com

VirusCancersMechanisms
HPV (16, 18, others)Cervical, oropharyngeal, anal, penile, vaginal, vulvarE6 degrades p53; E7 degrades pRb → genomic instability, immortalization
HBV / HCVHepatocellular carcinoma (HCC)HBV: integration → insertional mutagenesis, HBx protein; HCV: chronic inflammation, cirrhosis, core protein signaling
EBVBurkitt lymphoma, nasopharyngeal ca, gastric ca, HL, PTLDLatency programs (LMP1, EBNA2) → NF-κB, proliferation; genomic instability
KSHV (HHV-8)Kaposi sarcoma, PEL, MCDViral cyclin, FLIP, vGPCR → angiogenesis, proliferation, immune evasion
HTLV-1Adult T-cell leukemia/lymphoma (ATLL)Tax → NF-κB, CREB; HBZ → genomic instability; clonal expansion
MCPyVMerkel cell carcinomaT antigens → RB degradation, Wnt activation